Treximo

Is it software testing your quality assurance method? You can go one step further and avoid issues from the start with a Software Quality Assurance (SQA). High-quality developers who use SQA spend 22% less time fixing issues typically found during testing.

Whether you’re developing an EDC system for clinical patient data or your business uses data science to extrapolate interesting clinical trial information, SQA will help you solve problems before you have them. With Treximo’s technology consulting services, we can ensure your software is quality-checked and constantly improved. Learn more about SQA here: https://treximo.com/blog/what-is-software-quality-assurance/

Johnson & Johnson is inspiring patients through Twitter. In this program, patients recount their health stories and explain how a drug from J&J Janssen unit changed their lives. This is intended to bring people together, inspire and bring hope https://bit.ly/3gL1wV7

Johnson & Johnson takes to Twitter to expand its network of storytelling patients If you want to connect with and inspire your audience, tell them a story. That may be a marketing mantra, but it’s also the premise behind Johnson & Johnson's SHARE Network, a program that asks patients to recount their health stories—and share how a treatment from its Janssen unit changed their...

"Roche said its cancer drug Polivy combined with a common chemotherapy regimen held lymphoma in check for longer than the standard drugs alone in patients who had not been previously treated. The drug is the first treatment shown to improve outcomes in these patients in 20 years".

Read the full story here: https://www.biopharmadive.com/news/roche-polivy-first-line-lymphoma-car-t-study/604660/

Roche sets bar in early lymphoma treatment with Polivy study results Positive data for the Swiss pharma's antibody-based drug could be a benchmark for CAR-T therapies, which other developers aim to move into early lymphoma treatment, too.

A bioerodible implant with sustained-release technology will help prevent HIV infection and also provide birth control.

Inflammasome Therapeutics, which is behind this development, just received a grant from The Bill & Melinda Gates Foundation worth $1.3 million to continue this project, aligned with its objective of HIV prevention and expanding the range of contraceptive options for women: https://bit.ly/3kAUJ15.

Inflammasome gets Gates grant for dual HIV-birth control implant Inflammasome Therapeutics has received funding to develop a sustained-release formulation that provides protection from HIV infection and birth control for 12 months. The Bill & Melinda Gates Foundation is bankrolling the project through a $1.3 million grant.

Did you know that for every $1B invested in the US, $122M is lost to poor project management? Most businesses waste 12% on inefficiencies that project management can solve.

Discover the 6 benefits you can have in your Life-Science Company with a customized PMO service to manage many ongoing projects across various job sites, creating efficiency in resources and money: https://treximo.com/blog/6-benefits-of-custom-pmo-design/